Proprotein Convertase Subtilisin/Kexin Type 9 Induction in Hypercholesterinemic Patients With Primary and Metastatic Liver Tumors
Serum PCSK9 is increased in patients with CRC metastases or HCC with hypercholesterolemia. This suggests that patients with high cholesterol levels may benefit most from PCSK9 blockage.
Authors
- Thomas S. Weiß (ORCID: https://orcid.org/0000-0003-0336-0581)
- Christa Buechler (ORCID: https://orcid.org/0000-0002-5635-3994)
Institutions
- University Hospital Regensburg (DE)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21873/anticanres.17504
- Citations
- 3
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 2.81